Biocon Biologics Ltd. (BBL) has announced that the Government of Malaysia has agreed to extend the current contract period of 36 months under the existing insulin supply agreement with its subsidiary in Malaysia, Biocon Sdn. Bhd., and Duopharma Marketing Sdn. Bhd. (DMktg), for an additional six months, effective from April 29 to October 28, 2025.

Biocon Biologics has been supplying insulin products to the Ministry of Health in Malaysia for over a decade. The company also runs an integrated insulin manufacturing facility in Johor, in southern Malaysia. Biocon Biologics received US Food and Drug Administration (FDA) approval for this facility earlier this year, in January.

“Biocon Biologics is committed to enable affordable access to life-saving insulins to people with diabetes in Malaysia and other parts of the world,” said the company spokesperson in an official communique.  

The amendment to the contract will be formalised through the execution of a formal supplementary agreement between the MoH, DMktg and Biocon subsequently.